### Primaquine

**Indication**  
Malaria due to *Plasmodium vivax*  
*ICD11 code: 1F81*

**INN**  
Primaquine

**Medicine type**  
Chemical agent

**List type**  
Core

**Additional notes**  
Only for use to achieve radical cure of *P. vivax* and *P. ovale* infections, to be administered for 14 days

**Formulations**  
Oral > Solid: 7.5 mg tablet (as phosphate); 15 mg tablet (as phosphate)

**EML status history**  
- First added in 1977 ([TRS 615](https://trials.who.int/trialsearch/trial/615))
- Changed in 1979 ([TRS 641](https://trials.who.int/trialsearch/trial/641))
- Changed in 2007 ([TRS 946](https://trials.who.int/trialsearch/trial/946))
- Changed in 2007 ([TRS 950](https://trials.who.int/trialsearch/trial/950))

**Sex**  
All

**Age**  
Also recommended for children

**Therapeutic alternatives**  
The recommendation is for this specific medicine

**Patent information**  
Patents have expired in most jurisdictions  
[Read more about patents.](https://trials.who.int/trialsearch/trial/615)

**Wikipedia**  
[Primaquine](https://en.wikipedia.org/wiki/Primaquine)

**DrugBank**  
[Primaquine](https://www.drugbank.ca/drugs/DB00004)